Avidea’s polymer-drug conjugate (PDC) platforms overcome key hurdles for enabling successful immunotherapies. Learn more
Our team is building on more than two decades of pioneering work by our world-class scientific founders and advisors who are experts in immunology, oncology, vaccines and biomaterials.About us
Avidea is looking for highly motivated and talented individuals to join our team. Check out our careers page to learn about opportunities to join our growing team.Join us
Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cellsRead more
Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigensRead more
In vivo characterization of the physicochemical properties of polymers-linked TLR agonists that enhance vaccine immunogenicityRead more
March 25, 2021
February 1, 2021
Avidea Technologies and University of Maryland awarded grant to evaluate Avidea’s SNAPvaxTM tolerance vaccine for treating autoimmune diseases.
November 2, 2020
Avidea Technologies and collaborators publish Nature Immunology cover article describing MOA for improved cancer treatment efficacy with SNAPvax administered IV.
March 9, 2020
Avidea Technologies and collaborators publish cover article in Nature Biotechnology describing the systematic development of SNAPvax™ technology.